Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 243 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: EGFR Mutation Clear all

Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

View directory record Official record

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Oakland, California • Roseville, California • San Francisco, California + 13 more

Source: ClinicalTrials.gov public record

Updated May 14, 2026 · Synced May 22, 2026, 1:32 AM EDT

Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401

View directory record Official record

Conditions: EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions: E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection; Biological · Drug · Procedure
Lead sponsor: Hideho Okada, MD, PhD; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Source: ClinicalTrials.gov public record

Updated Mar 15, 2026 · Synced May 22, 2026, 1:32 AM EDT

Active, not recruiting Phase 1 Interventional

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

NCT05163028

View directory record Official record

Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Interventions: HBI-2376; Drug
Lead sponsor: HUYABIO International, LLC.; Industry
Eligibility: 18 Years and older

Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 11
States / cities: Duarte, California • Encinitas, California • Fullerton, California + 7 more

Source: ClinicalTrials.gov public record

Updated Sep 23, 2025 · Synced May 22, 2026, 1:32 AM EDT

Completed Phase 1 Interventional

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

NCT00372515

View directory record Official record

Conditions: Non-Small Cell Lung Cancer
Interventions: Gefitinib; Drug
Lead sponsor: David M. Jackman, MD; Other
Eligibility: 18 Years and older

Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Jan 30, 2018 · Synced May 22, 2026, 1:32 AM EDT

Recruiting Phase 3 Interventional

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277

View directory record Official record

Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older

Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 27
States / cities: Newport Beach, California • San Diego, California • San Francisco, California + 21 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 22, 2026, 1:32 AM EDT

Completed Phase 1 Interventional

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

NCT01337765

View directory record Official record

Conditions: Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
Interventions: BEZ235 + MEK162; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Source: ClinicalTrials.gov public record

Updated Oct 8, 2020 · Synced May 22, 2026, 1:32 AM EDT

Completed Phase 1 Interventional

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

NCT03685331

View directory record Official record

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
Interventions: Palbociclib, Olaparib, Fulvestrant; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only

Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Jan 8, 2026 · Synced May 22, 2026, 1:32 AM EDT

Recruiting No phase listed Observational

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

NCT03042221

View directory record Official record

Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years

Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Source: ClinicalTrials.gov public record

Updated Feb 19, 2026 · Synced May 22, 2026, 1:32 AM EDT

Recruiting Phase 3 Interventional

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521

View directory record Official record

Conditions: PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions: RLY-2608, Capivasertib, Fulvestrant; Drug
Lead sponsor: Relay Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 51
States / cities: Gilbert, Arizona • Beverly Hills, California • Duarte, California + 41 more

Source: ClinicalTrials.gov public record

Updated May 7, 2026 · Synced May 22, 2026, 1:32 AM EDT

Recruiting Phase 2 Interventional

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

NCT03191149

View directory record Official record

Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 344
States / cities: Anchorage, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 238 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 22, 2026, 1:32 AM EDT

Active, not recruiting Phase 2 Interventional

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

NCT03410043

View directory record Official record

Conditions: Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Osimertinib, Radiation Therapy, Therapeutic Conventional Surgery; Drug · Radiation · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: San Francisco, California • Denver, Colorado • New York, New York + 1 more

Source: ClinicalTrials.gov public record

Updated Apr 5, 2026 · Synced May 22, 2026, 1:32 AM EDT

Completed Phase 3 Interventional Results available

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02296125

View directory record Official record

Conditions: Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Interventions: AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Gefitinib 250 mg, Erlotinib 150/100 mg, Gefitinib 250 mg, Placebo AZD9291 80 mg/ 40 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 100 Years

Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 14
States / cities: Anaheim, California • Santa Rosa, California • West Hills, California + 10 more

Source: ClinicalTrials.gov public record

Updated Apr 20, 2026 · Synced May 22, 2026, 1:32 AM EDT

Active, not recruiting Phase 2 Interventional Results available

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

NCT02971501

View directory record Official record

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
Interventions: Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 18
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 11 more

Source: ClinicalTrials.gov public record

Updated Apr 27, 2026 · Synced May 22, 2026, 1:32 AM EDT

Terminated Phase 2 Interventional Results available

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

NCT04538378

View directory record Official record

Conditions: EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
Interventions: Olaparib, Durvalumab, EKG, Tumor biopsy, CT chest, abdomen and pelvis, MRI chest, abdomen and pelvis; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Jan 26, 2025 · Synced May 22, 2026, 1:32 AM EDT

Completed Phase 2 Interventional Results available

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

NCT02616393

View directory record Official record

Conditions: Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases
Interventions: Tesevatinib; Drug
Lead sponsor: Kadmon Corporation, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: Beverly Hills, California • Newport Beach, California • Santa Monica, California + 4 more

Source: ClinicalTrials.gov public record

Updated Mar 15, 2022 · Synced May 22, 2026, 1:32 AM EDT

Completed Phase 1Phase 2 Interventional Results available

AZD9291 First Time In Patients Ascending Dose Study

NCT01802632

View directory record Official record

Conditions: Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions: AZD9291; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years

Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Apr 19, 2026 · Synced May 22, 2026, 1:32 AM EDT

Terminated Phase 1 Interventional

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

NCT02468661

View directory record Official record

Conditions: Non-Small Cell Lung Cancer
Interventions: INC280 single agent, erlotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Detroit, Michigan + 2 more

Source: ClinicalTrials.gov public record

Updated Feb 23, 2020 · Synced May 22, 2026, 1:32 AM EDT

Recruiting Phase 1 Interventional

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

NCT07315113

View directory record Official record

Conditions: EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
Interventions: NXP900, Osimertinib; Drug
Lead sponsor: Nuvectis Pharma, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Houston, Texas • Fairfax, Virginia

Source: ClinicalTrials.gov public record

Updated Jan 1, 2026 · Synced May 22, 2026, 1:32 AM EDT

Completed Phase 1 Interventional

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

NCT03846310

View directory record Official record

Conditions: Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
Interventions: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated Dec 8, 2024 · Synced May 22, 2026, 1:32 AM EDT

Active, not recruiting Phase 3 Interventional Results available

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295

View directory record Official record

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Lazertinib, Amivantamab, Pemetrexed, Carboplatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 28
States / cities: Mobile, Alabama • Tucson, Arizona • Duarte, California + 23 more

Source: ClinicalTrials.gov public record

Updated May 7, 2026 · Synced May 22, 2026, 1:32 AM EDT

Active, not recruiting Phase 3 Interventional Results available

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080

View directory record Official record

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Osimertinib, Lazertinib, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 1,074 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 20
States / cities: Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more

Source: ClinicalTrials.gov public record

Updated May 7, 2026 · Synced May 22, 2026, 1:32 AM EDT

Completed Phase 2 Interventional Results available

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

NCT02414139

View directory record Official record

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Capmatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 13
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 10 more

Source: ClinicalTrials.gov public record

Updated Mar 19, 2024 · Synced May 22, 2026, 1:32 AM EDT

Completed Phase 2 Interventional Results available

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

NCT01573702

View directory record Official record

Conditions: Non Small Cell Lung Cancer
Interventions: Stereotactic Radiosurgery, Erlotinib; Procedure · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Chapel Hill, North Carolina + 5 more

Source: ClinicalTrials.gov public record

Updated Jan 11, 2021 · Synced May 22, 2026, 1:32 AM EDT

Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287

View directory record Official record

Conditions: Lung Cancer, Breast Cancer
Interventions: BMS-986507, Osimertinib, Pembrolizumab, Nivolumab, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older

Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 14
States / cities: Birmingham, Alabama • Miami, Florida • Maywood, Illinois + 9 more

Source: ClinicalTrials.gov public record

Updated May 6, 2026 · Synced May 22, 2026, 1:32 AM EDT